Revenue segments as reported by the company.

Consumer Health

Pharmaceutical

Medical Devices

Innovative Medicine

MedTech

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, marketing and administrative expenses

Research and development expense

In-process research and development

Interest expense

Other expense

Restructuring

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Johnson & Johnson

Band-Aid is a brand name of American pharmaceutical and medical devices giant Johnson & Johnson's line of adhesive bandages.

Band-Aid

Johnson's Baby is an American brand of baby cosmetics and skin care products owned by Johnson & Johnson. The brand dates back to 1893 when Johnson's Baby Powder was introduced. Product line consists of baby powder, shampoos, body lotions, massage oil, shower gels and baby wipes. The brand has reputation for making baby products that are "exceptionally pure and safe" since at least the 1980s.

Johnson's Baby

Aveeno is a brand of skin care and hair care products in the United States owned by American consumer goods and pharmaceutical company Johnson & Johnson. Aveeno was founded in 1945, and its first product was their Soothing Bath Treatment. The active ingredient in all Aveeno products are colloidal oats and/or oat extracts - Avenanthramides, which have been branded as "active naturals". Aveeno offers products to treat skin conditions such as eczema, psoriasis, urushiol-induced contact dermatitis, pruritus ani, chickenpox, hives, and sunburn.

Aveeno

Neutrogena is an American brand of skin care, hair care and cosmetics, that is headquartered in Los Angeles, California. According to product advertising at their website, Neutrogena products are distributed in more than 70 countries. Neutrogena was founded in 1930 by Emanuel Stolaroff, and was originally a cosmetics company named Natone. It is now part of the US-based Johnson & Johnson conglomerate, which bought the independent company in 1994.

Neutrogena

Clean & Clear is a line of dermatology products owned by Johnson & Johnson.

Clean & Clear

Listerine is a brand of antiseptic mouthwash product. It is promoted with the slogan "Kills germs that cause bad breath". Named after Joseph Lister, a pioneer of antiseptic surgery, Listerine was developed in 1879 by Joseph Lawrence, a chemist in St. Louis, Missouri.

Listerine

Acuvue (from "Accurate view") is a brand of disposable contact lenses made by Jacksonville-based Vistakon, a subsidiary of Johnson & Johnson (J&J).

Acuvue

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Johnson & Johnson reports solid Q4 earnings, eyes $60B Pharma revenue

Johnson & Johnson's Q4 2022 showed steady operational growth and strong financial performance. The company aims for continued growth in Pharmaceuticals, focusing on key products and pipeline advancements. Challenges include managing costs, addressing sales declines, and navigating market uncertainties.

Johnson & Johnson reports resilient Q1 performance amidst challenges

Johnson & Johnson's Q1 2023 performance reflects resilience and growth across key segments despite short-term challenges.
The company's strategic focus on innovation, resource management, and portfolio diversification positions it for future success.
While facing legal and financial headwinds, Johnson & Johnson remains optimistic about its outlook for 2023 and beyond.
Increased guidance, product developments, and commitment to safety and innovation underscore the company's long-term growth potential.

Johnson & Johnson reports strong Q2 earnings and strategic growth plans

Johnson & Johnson showcased robust financial results in Q2, raising full-year guidance and highlighting growth in MedTech and Pharmaceuticals. Despite challenges from pricing pressures and litigation, the company remains focused on strategic opportunities and maintaining a strong market position. With a clear focus on innovation and growth, Johnson & Johnson is poised for continued success in the healthcare sector.

Johnson & Johnson posts strong Q3 results amidst growth strategies

Johnson & Johnson (JNJ) delivered robust Q3 results, showcasing growth in sales, earnings, and operational efficiency across key segments, positioning the company for future success.
While facing challenges from geopolitical factors, legal issues, and upcoming competition, JNJ's strategic strengths in acquisitions, innovation, and market presence offer avenues for sustained growth.
With a focus on key brands, pipeline advancements, and MedTech innovations, JNJ remains poised to meet revenue targets, navigate challenges, and capitalize on market opportunities in the coming years.

Johnson & Johnson reports robust 2023 performance and strategic growth outlook

Johnson & Johnson's strong 2023 performance in Innovative Medicine and MedTech drove operational sales growth. Despite inflationary pressures impacting margins, JNJ remains focused on enhancing shareholder returns and pursuing strategic M&A deals. Opportunities for growth in 2024 include new product launches and advancements in key focus areas.

Johnson & Johnson posts strong Q1 earnings, eyes growth opportunities

Johnson & Johnson's Q1 2024 earnings reflect solid performance across key segments, with a focus on innovation and strategic growth initiatives.
Despite challenges in certain segments, the company's proactive approach to restructuring and market dynamics positions it for future success.
Opportunities in Vision Care, Pulmonary Hypertension, and Orthopaedics underscore potential for sustained growth and market leadership.
Overall, Johnson & Johnson's diversified product portfolio and financial outlook support confidence in achieving growth targets for 2024.

Johnson & Johnson posts strong Q2 results, eyes growth opportunities

Johnson & Johnson delivered a robust performance in Q2 2024, driven by strong sales growth in both Innovative Medicine and MedTech segments, supported by strategic initiatives.
While facing challenges in certain markets and the need for continued innovation, the company's outlook remains positive with a solid guidance for the full year 2024.
By capitalizing on opportunities in key products and markets, Johnson & Johnson is well-positioned to navigate challenges and drive sustainable growth in the healthcare sector.

Johnson & Johnson reports robust Q3 earnings amidst legal challenges

Johnson & Johnson's Q3 2024 earnings call showcased strong financial performance, driven by growth in key segments and successful product launches. Despite facing challenges with talc litigation, the company remains focused on innovation, capital allocation, and resolving legal issues.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Johnson & Johnson (NYSE: JNJ) is reportedly considering running a COVID-19 vaccine booster trial in South Africa after its jab was used in a mass trial of almost half a million health workers in the country.  The trial would include participants from that study, dubbed Sisonke, and could start in October, Bloomberg reported citing Glenda Gray, co-lead of the mass trial.

Johnson & Johnson Plans COVID-19 Booster Shot Trial In South Africa: Bloomberg

AstraZeneca

Pfizer

Roche Holding AG

Most Large Cap Pharmaceuticals industry players' Q2 results were strong. Regulatory/pipeline updates related to COVID-19 medicines/vaccines continue to take center stage.

4 Big Drugmaker Stocks to Watch Out For as Recovery Gains Steam

McDonald's

Procter & Gamble

Verizon

As an investor, retirement likely means you're looking for a combination of safety, income, and some growth potential in your portfolio. These stocks deliver in all three areas.

If You're Retired, Consider Buying These 5 Stocks

Apple

Salesforce

Cantaloupe, Inc

Dow Inc

Goldman Sachs

Home Depot

Hecla Mining

JPMorgan Chase & Co

Travelers

UnitedHealth Group

Two new Breakout Stocks for Week 36 with better than 10% short-term upside potential. The ETF/ETN forecast section now goes out in a separate article. Following the Momentum Gauges, the portfolio is up +57.6% YTD with a record high 20 out 35 weeks this year in negative conditions above the 40 MG level.

Week 36 MDA Breakout Stocks - September 2021: Short-Term Picks To Give You An Edge

Incyte

Tesla

Vertex Pharmaceuticals

According to Wall Street legend, a young person approached one of the top businessmen in the U.S. (said to be J.P. Morgan, the founder of his namesake bank J.P.

Insider Buying at These Biotech Companies Indicates Value

Insider Buying at These Biotech Firms Indicates Value

ATLANTIC CITY, N.J., Sept. 2, 2021 /PRNewswire/ -- In a new state court filing, women who hold Johnson & Johnson (NYSE:JNJ) and the company's iconic talc baby powder responsible for their ovarian cancer are seeking a temporary restraining order and preliminary injunction to prevent J&J, or any of its corporate affiliates, from fraudulently transferring assets to a subsidiary and plunging it into bankruptcy.

Battle Against Johnson & Johnson "Texas Two-Step" Ploy Moves to New Jersey

Johnson & Johnson (NYSE: JNJ) drew criticism two weeks ago amid reports that doses of its single-shot COVID-19 vaccine produced in South Africa were being exported to Europe. Read Next:   Europe Faces Backlash For Importing JNJ COVID-19 Shots From South Africa.

Europe To Return Johnson & Johnson COVID-19 vaccines Shipped From South Africa: WSJ

AbbVie

Baxter

Medtronic

Health Care Select Sector SPDR Fund

Covid-19 showed us how rapid advances in medicine and technology could create significant growth opportunities for healthcare stocks. The post 7 Healthcare Stocks to Buy Before $3.5 Trillion Floods In  appeared first on InvestorPlace.

7 Healthcare Stocks to Buy Before $3.5 Trillion Floods In

J&J (JNJ) gets FDA approval for its twice-a-year treatment option for schizophrenia patients, Invega Hafyera.

J&J (JNJ) Gets FDA Nod for Twice-Yearly Schizophrenia Drug

Bristol-Myers

Merck

Now is not the time to sell healthcare. Biopharma offers some of the highest quality bargains in the entire market right now.

4 Blue Chip Bargains In The Biopharma Space

J&J's (JNJ) mid-stage study shows HIV vaccine fails to provide enough protection against HIV in young women in Africa.

J&J's (JNJ) HIV Vaccine Study in Young African Women Fails

Amcor Plc

Caterpillar

Chevron

Nucor

Roper Technologies

The dividend aristocrat stocks are often looked over, but investors really should give them a look with their 10% plus returns and stability. The post 7 Dividend Aristocrat Stocks to Buy in September for Gains and Stability appeared first on InvestorPlace.

7 Dividend Aristocrat Stocks to Buy in September for Gains and Stability

MONTGOMERY, Ala., Aug. 31, 2021 /PRNewswire/ -- Another jury has found that Johnson & Johnson's (NYSE:JNJ) talcum powder products cause cancer, prompting attorneys representing thousands of cancer victims to demand that the company take responsibility for damages brought by its defective consumer products and its failure to warn generations of women about talc-cancer links.

Outcry Continues to Grow for Johnson & Johnson to Resolve Talc-Cancer Claims After Latest Jury Verdict

American Tower

Franklin Resources

International Paper

Leggett & Platt

New Linde PLC

LyondellBasell Industries

Microsoft

NIKE

Verizon Communications Inc 5.9 % Notes 2014-15.2.54 Sr

In Part 1 of this article, I presented the top 50 holdings of 50 dividend-paying ETFs, ranked by using a proportional scoring system that favors larger investments and larger ETFs. In Part 2a, I showcased the top Defensive Sector stocks. The article presented the seven top-ranked stocks in each of the Consumer Staples, Health Care, and Utilities sectors.

Top Holdings Of Dividend ETFs (Part 2b: The Top Cyclical Sector Stocks)

Johnson & Johnson (NYSE: JNJ) said on Tuesday its experimental vaccine for HIV failed to invoke a sufficient immune response in a study set in sub-Saharan Africa. Shares of the company are still more than 0.5% up this morning.

Johnson & Johnson discontinues HIV vaccine trial on insufficient efficacy

Johnson & Johnson (NYSE: JNJ) and a consortium of global partners announced results from the primary analysis of a Phase 2b HIV vaccine trial, Imbokodo study. Data showed that the investigational HIV vaccine regimen did not provide sufficient protection against HIV infection in a population of young women in sub-Saharan Africa at high risk of acquiring HIV.

Johnson & Johnson Stops HIV Vaccine Trial In African Women

NEW BRUNSWICK, N.J., Aug. 31, 2021 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ), together with a consortium of global partners, today announced results from the primary analysis of a Phase 2b HIV vaccine clinical trial known as the Imbokodo study (also known as HVTN 705/HPX2008).

Johnson & Johnson and Global Partners Announce Results from Phase 2b Imbokodo HIV Vaccine Clinical Trial in Young Women in Sub-Saharan Africa

New guidance from the National Institute for Health and Care Excellence (NICE) has rejected a combination regimen based on Johnson & Johnson's (NYSE: JNJ) Darzalex for previously untreated patients with multiple myeloma. The draft document covers the use of Darzalex (daratumumab) as an add-on to standard induction treatment with Takeda Pharmaceutical Co Ltd's (NYSE: TAK) Velcade (bortezomib) plus thalidomide and dexamethasone given to patients before a stem cell transplant.

UK's NICE Rejects Johnson & Johnson's Darzalex Regime For Newly Diagnosed Myeloma

American Express

Bonanza Creek Energy

Two new Breakout Stocks for Week 35 with better than 10% short-term upside potential. The ETF/ETN forecast section now goes out in a separate article. Following the Momentum Gauges, the portfolio is up +49.8% YTD with a record 20 out 34 weeks this year in negative signal conditions above the 40 MG level.

News for Johnson & Johnson Stock (JNJ)